Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MagForce AG : Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of MagForce AG



MagForce AG : Dr. Ben J. Lipps designated as Chairman of the Management Board
                  and Chief Executive Officer of MagForce AG

MagForce AG / Dr. Ben J. Lipps designated as Chairman of the Management Board
and Chief Executive Officer of MagForce AG . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the content of this
announcement.

Berlin, Germany, June 14, 2013 - The Supervisory Board of Magforce AG
(Frankfurt, XETRA: MF6), a leading medical device company in the field of
oncology, has appointed Dr. Ben J. Lipps, former CEO and Chairman of Fresenius
Medical Care, as Chairman of the Management Board and Chief Executive Officer
of the company starting September 2013. While serving as Chairman and CEO of
Magforce, Ben Lipps will continue his consultantship with Fresenius Medical
Care. The current management board members of Magforce Prof. Dr. Hoda Tawfik
(Chief Developement & Medical Officer) and Christian von Volkmann (Chief
Financial Officer) remain in their respective position.

Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management
Board of Fresenius Medical Care in May 1999. In December 2012, he stepped down
as Chairman of the Management Board and CEO. Dr. Lipps led the research team
that developed the first commercial hollow fiber artificial kidney at the end
of the 1960's. Today over two million dialysis patients rely on hollow fiber
dialyzers for life sustaining treatments.

Norbert Neef, Chairman of the Supervisory Board of MagForce, comments:
"MagForce is very proud to have attracted a former DAX 30 CEO as addition to
MagForce's management team. Dr. Lipps will help us harvesting the full
potential of our great IP. Based on the already existing regulatory approval
for our NanoTherm® Therapy for all forms of brain cancer we are confident to
be able to develop MagForce into a global medical device company successfully
targeting the treatment of multiple cancer forms."

Ben Lipps comments: "MagForce is a most interesting opportunity in the medical
device and pharma world. Globally, over two million patients are diagnosed
with brain, head & neck, and prostate cancers each year. Clearly, the
NanoTherm® Therapy being developed by MagForce AG can be applied as an adjunct
or as a monotherapy to assist in the treatment regiments for these solid
tumors. NanoTherm® Therapy has regulatory approval in 27 European countries
already. I am looking forward to work with the very competent and highly
motivated management team at MagForce. Our focus will be to advance this
therapy to the next level with its widespread commercialization and to
building a global player in the area of cancer treatment for the good of
patients".

About MagForce AG

MagForce AG is a leading medical  device company in the field of  nanomedicine 
in oncology, listed in  the entry standard  (MF6). The Company's  proprietary, 
NanoTherm^® therapy, enables  the targeted treatment  of solid tumors  through 
the intratumoral  generation  of  heat  via  activation  of  superparamagnetic 
nanoparticles. NanoTherm^®, NanoPlan^®,  and NanoActivator(TM) are  components 
of the  therapy  and have  received  EU-wide regulatory  approval  as  medical 
devices for the treatment of brain tumors. MagForce, NanoTherm^®,  NanoPlan^®, 
and NanoActivator(TM) are trademarks of MagForce AG in selected countries. For
more information, please visit www.magforce.com.

Full Resume Dr. Ben Lipps

Dr. Ben J. Lipps became Chairman and Chief Executive Officer of the Management
Board of Fresenius Medical Care in May 1999. In December 2012 he stepped  down 
as Chairman  of the  Management  Board and  CEO.  During his  term,  Fresenius 
Medical Care's sales tripled from 3.8 to 12.8 billion dollars, and the  annual 
net profit grew 6 times to 1.1 billion dollars.

He was also Chief  Executive Officer of Fresenius  Medical Care North  America 
until  February  2004.  He  was  President,  Chief  Executive  Officer,  Chief 
Operating Officer and a  director of Fresenius USA  from October 1989  through 
February  2004,  and  served  in  various  capacities  with  Fresenius   USA's 
predecessor from 1985 through 1989.

He earned his master's and doctoral degrees at the Massachusetts Institute  of 
Technology in  chemical engineering.  Before joining  the Fresenius  Group  in 
1985,  Dr.  Lipps  held  several  research  management  positions  in  various 
companies, among them with DOW Chemical.

Disclaimer

This release may contain forward-looking statements and information which  may 
be  identified  by  formulations  using  terms  such  as  "expects",   "aims", 
"anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will".
Such forward-looking  statements are  based on  our current  expectations  and 
certain  assumptions,  which  may  be  subject  to  a  variety  of  risks  and 
uncertainties. The results actually achieved by MagForce AG may  substantially 
differ  from  these  forward-looking   statements.  MagForce  AG  assumes   no 
obligation to update these  forward-looking statements or  to correct them  in 
case of developments, which differ from those, anticipated.

MagForce_Press Release_June 14, 2013

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: MagForce AG via Thomson Reuters ONE
HUG#1709683

--- End of Message ---

MagForce AG
Max-Dohrn-Str. 8 Berlin Germany

WKN: A0HGQF;ISIN: DE000A0HGQF5;
Listed: Open Market (Freiverkehr) in Frankfurter Wertpapierbörse;
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement